Comparison of Self-Reported and Objective Adherence to Antiglaucoma Medications

Żarnowski, Tomasz; Wyszyńska, Anna; Rękas, Marek

doi:10.1089/jop.2016.0052

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The failure of younger patients to adhere to a daily administration of eye drops may be mainly of psychological nature, but older patients are often simply not able to administer the medicine on their own due to the presence of concomitant health conditions, such as hand tremor. Moreover, a study which employed a device that allows electronic monitoring of adherence (Travatan Dosing Aid; Alcon) indicated that the real adherence rate may be much lower than self-reported by the patients [7]. When adherence to treatment was compared across six major classes of medicines for chronic conditions based on a multi-million database of pharmacy claims, anti-glaucoma eye drops containing prostaglandin analogues rated the second worst, with a mean 12-month adherence rate of 37% [8].…”

Section: Introductionmentioning

confidence: 99%

Peripheral Latanoprost Administration Lowers Intraocular Pressure in the Wistar Rat

et al. 2020

View full text Add to dashboard Cite

Purpose: Instillation of latanoprost eye drops into the conjunctival sac to lower intraocular pressure (IOP) is the most frequently used treatment for primary open-angle glaucoma. The aim of this study was to evaluate the influence of latanoprost on IOP in the rat when applied peripherally. Methods: A rodent-dedicated tonometer was used to measure IOP in conscious adult male normotensive Wistar rats habituated to the measurement procedure. Commercially available 0.005% latanoprost solutions were continuously delivered to the periphery of the eye over 7 days using mini-pumps inserted subcutaneously in the animal's back, and IOP was measured daily. For comparison, a solution containing an equimolar concentration of latanoprost acid, an active compound of latanoprost, was similarly infused into the eyes of different Wistar rats. Results: Continuous subcutaneous infusion of latanoprost gradually decreased the IOP; the stable nadir of IOP, which was 20% lower than that prior to the start of infusion, was reached on day 3. The effect was statistically significant and fully reversed 2 days after cessation of drug delivery. Continuous subcutaneous application of the solution containing an equimolar amount of latanoprost acid did not appreciably influence the IOP. Conclusion: Subcutaneous continuous delivery of latanoprost decreased the IOP in the conscious normotensive Wistar rats in this study. If this effect is confirmed in humans, it may open the possibility of using peripheral systems of drug delivery, which could significantly improve patient compliance.

show abstract

Section: Introductionmentioning

confidence: 99%